Uniqure’s accelerated approval hopes take a hit

Uniqure’s Huntington’s disease gene therapy AMT-130 might be one of biotech’s most valuable unpartnered assets, but its track record of disappointments suggests why big groups remain uninterested. Today brought further pain, as confusing biomarker data that could imperil AMT-130’s accelerated approval chances wiped 45% off Uniqure’s share price.